PNV Stock Overview
Designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PNV from our risk checks.
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.58 |
| 52 Week High | AU$2.78 |
| 52 Week Low | AU$1.10 |
| Beta | 1.67 |
| 11 Month Change | 0.39% |
| 3 Month Change | 10.26% |
| 1 Year Change | 86.28% |
| 33 Year Change | 29.32% |
| 5 Year Change | 15.18% |
| Change since IPO | 1,190.00% |
Recent News & Updates
Recent updates
PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital
Aug 28
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
Aug 06PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
May 08When Should You Buy PolyNovo Limited (ASX:PNV)?
Feb 28Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S
Feb 02PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 08Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?
Sep 22When Should You Buy PolyNovo Limited (ASX:PNV)?
Jun 26Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?
May 30Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price
Apr 18Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?
Mar 23Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?
Feb 05Returns At PolyNovo (ASX:PNV) Are On The Way Up
Nov 16PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price
Nov 01What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?
Jul 29PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital
Jun 15Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)
May 16We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt
Apr 28There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital
Mar 07Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?
Dec 13PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why
Oct 19Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?
May 08News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat
Feb 27Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts
Feb 25Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?
Feb 17These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat
Jan 14
Breakeven Is Near for PolyNovo Limited (ASX:PNV)
Dec 28Shareholder Returns
| PNV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 10.7% | 0.5% | 1.2% |
| 1Y | 86.3% | 10.7% | 11.7% |
Return vs Industry: PNV exceeded the Australian Medical Equipment industry which returned 10.7% over the past year.
Return vs Market: PNV exceeded the Australian Market which returned 11.7% over the past year.
Price Volatility
| PNV volatility | |
|---|---|
| PNV Average Weekly Movement | 7.3% |
| Medical Equipment Industry Average Movement | 9.5% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: PNV has not had significant price volatility in the past 3 months.
Volatility Over Time: PNV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 254 | Swami Raote | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| PNV fundamental statistics | |
|---|---|
| Market cap | AU$1.75b |
| Earnings (TTM) | AU$5.26m |
| Revenue (TTM) | AU$103.23m |
338.7x
P/E Ratio17.3x
P/S RatioIs PNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNV income statement (TTM) | |
|---|---|
| Revenue | AU$103.23m |
| Cost of Revenue | AU$16.41m |
| Gross Profit | AU$86.82m |
| Other Expenses | AU$81.56m |
| Earnings | AU$5.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0076 |
| Gross Margin | 84.11% |
| Net Profit Margin | 5.10% |
| Debt/Equity Ratio | 3.6% |
How did PNV perform over the long term?
See historical performance and comparison